Bitcoin exchange-traded funds (ETFs) attracted $301 million in new investments, reversing a two-week trend of outflows. This inflow signals renewed investor interest in Bitcoin through ETFs, which are popular for providing easier access to cryptocurrency exposure. The comeback may indicate growing confidence or positive market sentiment toward Bitcoin. Investors will watch if this trend continues amid ongoing market fluctuations.
Bitcoin's recent market activity is provided here as context for readers, with Pluang data as of Oct 26, 2026 17:21 WIB. Among 50 major cryptocurrencies priced on Pluang, 26 rose and 22 fell today. Notable movers include CAKE at Rp38.461 with a 1-day change of +3.32% and a Pluang order activity of 94% Sell / 6% Buy, ALGO at Rp1.888 with +2.55% change and 98% Sell / 2% Buy activity, and BCH at Rp5.026.753 with +2.49% change and 81% Sell / 19% Buy activity. The most notable figure is CAKE's 94% Sell order activity.
Corxel Pharmaceuticals US and Amanat Acquisition Corp have agreed to merge, creating a publicly traded biopharmaceutical company focused on oral obesity treatments. The deal will raise approximately $377 million, including $300 million from private i...
Eikon Therapeutics presented updated data on EIK1001, a TLR7/8 dual-agonist, combined with pembrolizumab and chemotherapy for stage 4 non-small cell lung cancer (NSCLC) at the 2026 ESMO Congress. The treatment showed a 72% objective response rate and...
Microsoft, Alphabet, and Amazon together represent about 15% of the S&P 500 index. All three tech giants are scheduled to report their quarterly earnings within a two-day span. These earnings reports are highly anticipated as they provide insight int...
Conow, in partnership with Tuya Smart, has introduced the Atlas 6000 AC in Germany, a 6 kWh AC-coupled plug-and-play home battery designed to upgrade existing rooftop solar systems. This battery features AI-driven energy management that optimizes hou...
BioNTech and DualityBio announced that their Phase-3 clinical trial DYNASTY-Breast02 met its primary endpoint, demonstrating a statistically significant but moderate improvement in progression-free survival for Trastuzumab Pamirtecan compared to chem...
